FORM 4	4
--------	---

Check this box if no	
longer subject to	
Section 16. Form 4 or	•
Form 5 obligations	
may continue. See	
Instruction 1(b).	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of LEVINE JACK	2. Issuer Name EzFill Holdin			0,	/mbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director10% Owner					
(Last) C/O EZFILL HOLI BISCAYNE BLVD	3. Date of Earlies 11/05/2021	st Transact	ion (Month/Da	y/Yeai	Officer (give title below)	Other (spec	cify below)			
MIAMI, FL 33137	4. If Amendment	, Date Ori	ginal	Filed(Mont	th/Day/Y	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Т	able I - N	on-D	erivative	Secur	ities Acq	uired, Disposed of, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)		(Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code		(A) or Disposed of (D) (Instr. 3, 4 and 5)		1 of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership
				Code	v	Amount	or (D)	Price		(Instr. 4)	
Common Stock		11/05/2021		А		20,477 (1)	А	\$ 2.939	33,763	D	
Common Stock									186,010	Ι	Cameo Life Sciences Investments LLC ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned dire	ctly or indirectly.	
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5.		6. Date Exer	cisable	7. Tit	tle and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transacti	on	Number		and Expiration	on Date	Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		of (Month/Day/Year)		Unde	erlying	Security	Securities	Form of	Beneficial		
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Deriv	ative			Secu	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Secur	Securities (I		(Instr. 3 and			Owned	Security:	(Instr. 4)	
	Security					Acqu	ired			4)			Following	Direct (D)	
						(A) o							1	or Indirect	
					Disposed							Transaction(s)			
						of (D)							(Instr. 4)	(Instr. 4)	
						(Instr. 3,									
					4, and 5)		15)								
											Amount				
								Date	Expiration		or				
								Exercisable		Title	Number				
								LACICISADIC	Date		of				
				Code	V	(A)	(D)				Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LEVINE JACK C/O EZFILL HOLDINGS, INC. 2125 BISCAYNE BLVD, #309 MIAMI, FL 33137	Х						

Signatures

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On 11/05/2021, Mr. Levine was awarded \$60,000 worth of restricted common stock pursuant to the EzFill 2020 Incentive Compensation Plan, with the common stock (1) valued at the closing price on November 4, 2021 (\$2.93 per share). These restricted shares of common stock will vest at the Company's next annual shareholders' meeting only if Mr. Levine remains a member of the Company's board of directors until such meeting.
- (2) Jack Levine is the Manager of Cameo Life Sciences Investments LLC and beneficially owns 186,010 shares of common stock, which are held by Cameo Life Sciences Investments, LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.